Cipla Ltd. — Capital/Financing Update 2022

Dec 30, 2022

• (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001
  • Scrip Code: 500087
• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg
• (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ

Sub: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that Cipla (EU) Limited, United Kingdom, ("Cipla EU"), wholly owned subsidiary of Cipla Limited, has entered into definitive agreements on 29th December 2022 for acquisition of ~10.35% of the registered share capital of Ethris GmbH, Germany.

Details required to be disclosed under the SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 have been provided in Annexure – I to this letter.

Please take the above information on record.

Thank you

Yours faithfully, For Cipla Limited

RAJENDRA KUMAR CHOPRA Digitally signed by RAJENDRA KUMAR CHOPRA Date: 2022.12.29 20:51:05 +05'30'

Rajendra Chopra Company Secretary

Prepared by: Simona Dsouza

Cipla Ltd.

Annexure – I

Details required to be disclosed as per SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015

Sr.	Particulars	Details
No.
a)	Name of the target entity, details in brief	Name of the target entity: Ethris GmbH("Ethris")
	such as size, turnover etc.;
		Details: Ethris,a limited liability companyBrief
		incorporatedunderthelawsofGermanyand
		registered with the commercial register of the local
		court of Munich under HRB 182200is a pre-clinical
		stage firm working on a proprietary non-immunogenic
		mRNA platform.
		million as on 31st DecemberTurnover: EUR5.452021.
b)	Whethertheacquisitionwouldfall	Acquisition does not fall within the purview of related
	within related party transaction(s) and	party transactions.
	whetherthepromoter/promoter
	group/groupcompanieshaveany	Noneofthepromoter/promotergroup/group
	interest in the entity being acquired? If	companies have any interest in the entity.
	yes, nature of interest and details
	thereof and whether the same is done at
c)	"arm's length";Industry to which the entity being	Research & Development(R&D)Industry: R&Dof new
	acquired belongs;	therapeutic procedures and products for the treatment
		of acquired and congenital diseases.
d)	Objectsandeffectsofacquisition	Investment in Ethris willprovideCipla access to its
	(including but not limited to, disclosure	mRNAplatformandthemRNA-basedproducts
	of reasons for acquisition of target	developed by Ethris
	entity, if its business is outside the main
	line of business of the listed entity);
e)	Brief details of any governmental or	Not applicable.
	regulatory approvals required for the
	acquisition;
f)	Indicative time-period for completion of	The transaction is expected to get completed within 60
	the acquisition;	days from the date of signing of the agreement or such
		other time-period as may be mutually agreed between
		the parties in writing and shall be subject to completion
		of necessary regulatory formalities.

g)	Nature of consideration -whether cashconsideration or share swap and detailsof the same;	Cash consideration.
h)	Cost of acquisition or the price at whichthe shares are acquired	Cipla EU to invest EUR 15 million for acquisition of9,939 common shares of face value of EUR 1 each, for
i)	Percentage of shareholding / controlacquired and / or number of sharesacquired;	a stake of ~10.35% of the registered share capitalofEthris.
j)	Briefbackgroundabouttheentityacquired in terms of products/line ofbusinessacquired,dateofincorporation, history of last 3 years'	Brief background: Please refer(a) above.Date of Incorporation: 26th October 2009
	turnover, country in which the acquired	History of last 3 years turnover:
	entity has presence and any othersignificant information (in brief)	For the year ended:
		31st December 2021: EUR5.45million
		31st December 2020: EUR 16.82 million31st December 2019: EUR 5.81 million
		Country: Germany